Cayman 6-(4-Methoxyphenyl)-3-Pyridazinamine; Purity- Greater Than

Piroxicam-d₃ is intended for use as an internal standard for the quantification of piroxicam (Item No. ) by GC- or LC-MS. Piroxicam is a COX inhibitor and non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory and analgesic properties.^, It inhibits production of thromboxane B₂ (TXB₂; Item No. ) from arachidonic acid (Item Nos. | | ) in HEL human erythroleukemic cells (IC₅₀ = 0.45 µM), which endogenously express COX-1, as well as inhibits LPS-induced formation of prostaglandin F_1α (PGF_1α; Item No. ) from arachidonic acid in Mono-Mac-6 cells (IC₅₀ = 0.77 µM), which endogenously express COX-2. Lornoxicam reduces LPS-induced production of nitric oxide and IL-6 in cell-based assays with IC₅₀ values of 240 and ~470 µM, respectively. It reduces carrageenan-induced paw edema in rats when administered at doses of 1, 2.5, and 5 mg/kg. Formulations containing piroxicam have been used in the treatment of pain and inflammation associated with osteoarthritis and rheumatoid arthritis.

WARNING This product is not for human or veterinary use.